Is targeted opioid therapy within sight?

Minerva Anestesiologica

Volumn 78, Issue 4, 2012, Pages 462-472

  Finco, G ^a   Pintor, M ^a   Sanna, D ^a   Orru G ^a   Musu, M ^a   Conno, F D ^b   Marchi, A ^a   Paribello, F ^a   D'Aloja, E ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Genetic; Opioids; Outcome assessment; Polymorphism

Indexed keywords

CATECHOL METHYLTRANSFERASE; CYTOCHROME P450 2D6; DELTA OPIATE RECEPTOR; FATTY ACID AMIDASE; GUANOSINE TRIPHOSPHATE CYCLOHYDROLASE I; MELANOCORTIN 1 RECEPTOR; MORPHINE; MU OPIATE RECEPTOR; MULTIDRUG RESISTANCE PROTEIN 1; OPIATE; TRANSIENT RECEPTOR POTENTIAL CHANNEL A1; VANILLOID RECEPTOR 1; NARCOTIC ANALGESIC AGENT;

ANALGESIA; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; MOLECULARLY TARGETED THERAPY; NOCICEPTION; OUTCOME ASSESSMENT; PAIN; PAIN THRESHOLD; PHARMACOGENETICS; PHENOTYPE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; EVIDENCE BASED MEDICINE; GENETICS; METHODOLOGY; PALLIATIVE THERAPY; PERSONALIZED MEDICINE;

ANALGESICS, OPIOID; EVIDENCE-BASED MEDICINE; HUMANS; INDIVIDUALIZED MEDICINE; PAIN; PAIN MANAGEMENT; PALLIATIVE CARE; POLYMORPHISM, SINGLE NUCLEOTIDE; TREATMENT OUTCOME;

EID: 84859394384     PISSN: 03759393     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Mogil JS, Sternberg WF, Marek P, Sadowski B, Belknap JK, Liebeskind JC. The genetic of pain and pain inhibition. Proc Natl Acad Sci USA 1996; 93:3048-55.
2. Mogil JS. The genetic mediation of individual differences in sensitivity to pain and its inhibition. Proc Natl Acad Sci USA 1999;96:7744-51.
3. Mogil JS. Animal models of pain: progress and challenges. Nat Rev Neurosci 2009;10:283-94.
4. Colson NJ, Fernandez F, Lea RA, Griffiths LR. The search for migraine genes: an overview of current knowledge. Cell Mol Life Sci 2007;64:331-4.
5. Tegeder I. Current evidence for a modulation of low back pain by human genetic variants. J Cell Mol Med 2009;13:1605-19.
6. Fillingim RB, Wallace MR, Herbstman DM, Ribeiro-Dasilva M, Staud R. Genetic contribution to pain: a review of findings in humans. Oral Diseas 2008;14:673-82.
7. Skorpen F, Laugsand EA, Klepstad P, Kaasa S. Variable response to opioid treatment: any genetic predictors within sight? Palliative Medicine 2008;22:310-27.
8. Zubieta JK, Heitzeg MM, Smith YR, Bueller JA, Xu K, Xu Y et al. COMT val158met genotype affects muopioid neurotransmitter responses to a pain stressor. Science 2003;299:1240-3.
9. Diatchenko L, Slade GD, Nackley AG, Bhalang K, Sigurdsson A, Belfer I et al. Genetic basis for individual variations in pain perception and the development of a chronic pain condition. Hum Mol Genet 2005;14:135-43.
10. Diatchenko L, Nackley AG, Slade GD, Bhalang K, Belfer I, Max MB et al. Catechol-O-methyltransferase gene polymorphisms are associated with multiple pain-evoking stimuli. Pain 2006;125:216-24.
11. Rakvåg TT, Ross JR, Sato H, Skorpen F, Kaasa S, Klepstad P. Genetic variation in the catechol-O-methyltransferase (COMT) gene and morphine requirements in cancer patients with pain. Mol Pain 2008;18;4:64.
12. Jensen KB, Lonsdorf TB, Schalling M, Kosek E, Ingvar M. Increased sensitivity to thermal pain following a single opiate dose is influenced by the COMT val(158)met polymorphism. PLoS One 2009;4:e6016.
13. Kim H, Lee H, Rowan J, Brahim J, Dionne RA. Genetic Polymorphisms in monoamine neurotransmitter systems show only weak association with acute post surgical pain in humans. Mol Pain 2006;2:24.
14. Oertel BG, Kettner M, Scholich K, Renné C, Roskam B, Geisslinger G et al. A common human mu-opioid receptor genetic variant diminishes the receptor signaling efficacy in brain regions processing the sensory information of pain. J Biol Chem 2009;284:6530-5.
15. Smith HS. Variations in opioid responsiveness. Pain physician 2008;11:237-48.
16. Rollason V, Samer C, Piguet V, Dayer P, Desmeules J. Pharmacogenetics of analgesics: toward the individualization of prescription, Pharmacogenomics 2008;9:905-33.
17. Fillingim RB, Kaplan L, Staud R, Ness TJ, Glover TL, Campbell CM et al. The A118G single nucleotide polymorphism of the muopioid receptor gene (OPRM1) is associated with pressure pain sensitivity in humans. J Pain 2005;6:159-67.
18. Klepstad P, Rakvåg TT, Kaasa S, Holthe M, Dale O, Borch-Grevink PC et al. The 118 A > G polymorphism in the human muopioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol Scand 2004;48:1232-9.
19. Kasai S, Hayashida M, Sora I, Ikeda K. Candidate gene polynorphisms predicting individual sensitivity to opioids. Naunyn. Schmiedeberg's Arch Pharmacol 2008;377:269-81.
20. Walter C, Lötsch J. Meta-analysis of the relevance of the OPRM1 118A>G genetic variant for pain treatment. Pain 2009;146:270-5.
21. Xuei X, Flury-Wetherill L, Bierut L, Dick D, Nurnberger J Jr, Foroud T et al. The opioid system in alcohol and drug dependence: family-based association study. Am J Med Genet B Neuropsychiatr Genet 2007;144B:877-84.
22. Chou WY, Yang LC, Lu HF, Ko JY, Wang CH, Lin SH et al. Association of mu-opioid receptor gene polymorphism (A118G) with variations in morphine consumption for analgesia after total knee arthroplasty. Acta Anaesthesiol Scand 2006;50:787-92.
23. Oertel BG, Schmidt R, Schneider A, Geisslinger G, Lötsch J The mu-opioid receptor gene polymorphism 118A>G depletes alfentanil-induced analgesia and protects against respiratory depression in homozygous carriers. Pharmacogenet Genomics 2006;16:625-36.
24. Hirota T, Ieiri I, Takane H, Sano H, Kawamoto K, Aono H et al. Sequence variability and candidate gene analysis in two cancer patients with complex clinical outcomes during morphine therapy. Drug Metab Dispos 2003;31:677-80.
25. Landau R, Kern C, Columb MO, Smiley RM, Blouin JL. Genetic variability of the mu-opioid receptor influences intrathecal fentanyl analgesia requirements in laboring women. Pain 2008;139:5-14.
26. Janicki PK, Schuler G, Francis D, Bohr A, Gordin V, Jarzembowski T et al. A genetic association study of the functional A118G polymorphism of the human mu-opioid receptor gene in patients with acute and chronic pain. Ansth Analg 2006;103:1011-7.
27. Zhang W, Yuan JJ, Kan QC, Zhang LR, Chang YZ, Wang ZY. Study of the OPRM1 A118G genetic polymorphism associated with postoperative nausea and vomiting induced by fentanyl intravenous analgesia. Minerva Anestesiol 2011;77:33-9.
28. Lotsch J, Geisslinger G. A critical appraisal of human genotyping for pain therapy. Trends in Pharmacological Sciences 2010;31:312-7.
29. Walter C, Lötsch J. Meta-analysis of the relevance of the OPRM1 118A>G genetic variant for pain treatment. Pain 2009;146:270-5.
30. Kim H, Mittal DP, Iadarola MJ, Dionne RA. Genetic predictors for acute experimental cold and heat pain sensitivity in humans. J Med Genet 2006;43:e40.
31. Oertel B, Lotsch J. Genetic mutations that prevent pain: implications for future pain medications. Pharmacogenomics 2008;9:179-94.
32. Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med 2004;351:2827-31.
33. Koren G, Cairns J, Chitayat D, Gaedigk A, Leeder SJ. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet 2006;368:704.
34. Smith HS. Variations in opioid responsiveness. Pain Physician 2008;11:237-48.
35. Persson E, Rhodin A. Genetics and pain. J Pain Palliat Care Pharmacother 2008;22:232-5.
36. Maddocks I, Somogyi A, Abbott F, Hayball P, Parker D. Attenuation of morphine-induced delirium in palliative care by substitution with infusion of oxycodone. J Pain Symptom Manage1996;12:182-9.
37. Mogil JS, Ritchie J, Smith SB, Strasburg K, Kaplan L, Wallace MR et al. Melanocortin-1 receptor gene variants affect pain and muopioid analgesia in mice and humans. Med Genet 2005;42:583-7.
38. Liem EB, Joiner TV, Tsueda K, Sessler DI. Increased sensitivity to thermal pain and reduced subcutaneous lidocaine efficacy in redheads. Anesthesiology 2005;102:509-14.
39. Klepstad P, Dale O, Borchgrevink PC, Kaasa S, Skorpen F. Genetic variation important for the clinical effect of opioids? Tidsskr Nor Laegeforen 2005;125:2655-8.
40. Skarke C, Jarrar M, Schmidt H, Kauert G, Langer M, Geisslinger G et al. Effects of ABCB1 (multidrug resistance transporter) gene mutations on disposition and central nervous effects of loperamide in healthy volunteers. Pharmacogenetics 2003;13:651-60.
41. Campa D, Gioia A, Tomei A, Poli P, Barale R. Association of ABCB1/MDR1and OPRM1 gene polymorphisms with morphine pain relief. Clin Pharmacol Ther 2008;83:559-66.
42. Tegeder I, Adolph J, Schmidt H, Woolf CJ, Geisslinger G, Lötsch J. Reduced hyperalgesia in homozygous carriers of a GTP cyclohydrolase 1 haplotype. Eur J Pain 2008;12:1069-77.
43. Tegeder I, Costigan M, Griffin RS, Abele A, Belfer I, Schmidt H et al. GTP cyclohydrolase and tetrahydrobiopterin regulate pain sensitivity and persistence. Nat Med 2006;12:1269-77.
44. Kim H, Dionne RA. Lack of influence of GTP cyclohydrolase gene (GCH1) variations on pain sensitivity in humans. Mol Pain 2007;7:6.
45. Park JJ, Lee J, Kim MA, Back SK, Hong SK, Na HS. Induction of total insensitivity to capsaicin and hypersensitivity to garlic extract in human by decreased expression of TRPV1. Neurosci Lett 2007;411:87-91.
46. Hapgood R. The potential and limitations of personalized medicine in the doctor-patient relationship. Pharmacogenomics 2003;4:685-7.
47. Dunn KM, Saunders KW, Rutter CM, Banta-Green CJ, Merrill JO, Sullivan MD et al. Opioid prescription for chronic pain and overdose. A cohort study. Annals of Internal Medicine 2009;152:85-92.
48. Mannelli P, Patkar A, Rozen S, Matson W, Krishnan R, Kaddurah-Daouk R. Opioid use affects antioxidant activity and purine metabolism: preliminary results. Hum Psychopharmacol 2009;24:666-75.